Synthesis of a tritiated human growth hormone rele... - GHRP-6 Study

Key Findings

A tritiated GHRP‑6 was synthesized with a specific activity of 29 Ci/mmol and 95% radiochemical purity.

The tritium atoms were mainly incorporated at the 5,7‑positions of the indole ring in the D‑Trp residue.

Anisole interfered with the dibromo‑indole during HF cleavage, so a modified deprotection method was required.

Practical Outcomes

This research provides a method for creating a radioactive GHRP‑6 for scientific studies, but it offers no actionable information for dosing, safety, or performance benefits. Biohackers looking to use GHRP‑6 for longevity or strength will not gain any direct guidance from this work.

Summary

The paper explains how scientists made a radioactive version of the GHRP‑6 peptide for lab experiments. It focuses on chemistry tricks to attach tritium and verify its purity, not on how the peptide works in the body or how to use it for health or performance.

Abstract

Tritium-labeled growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 was synthesized by tritium-halogen exchange on the precursor His-5,7-Br2-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The radiolabeled peptide had a specific activity of 29 Ci/mmol and a radiochemical purity of 95%. The tritium label was shown by 3H NMR to be located mostly at the expected 5,7-positions of the indole nucleus in the D-Trp residue. The dibromopeptide was prepared by solid-phase peptide synthesis, employing racemic 5,7-Br2-Trp as a building block and separation of the resulting epimeric mixture by HPLC. 5,7-Br2-Trp was prepared by a five-step sequence beginning with 2,4-dibromoaniline. The use of anisole as an additive in the HF resin/peptide cleavage was rejected because anisole was found to undergo electrophilic substitution of the dibromoindole nucleus; a modified HF deprotection/cleavage procedure was developed and used instead.

Study Information

Provider

pubmed

Year

1993

DOI

10.1111/j.1399-3011.1993.tb00150.x